SCHEMBL29777431

SCHEMBL29777431

C=C1C(=O)N[C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(=O)O)[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](/C=C/C(C)=C/[C@H](C)[C@H](Cc2ccccc2)OC)[C@H](C)C(=O)N[C@@H](C(=O)O)CCC(=O)N1C

nearest known ligand 0.95

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.95
TFPI2 P48307 2/20 0.95
NPY4R P50391 2/20 0.95
PPP5C P53041 2/20 0.95
PPM1A P35813 1/20 0.95
PPP1CC P36873 1/20 0.95
PPP2R2A P63151 1/20 0.95
PPP2R5A Q15172 1/20 0.95
SLCO1B3 Q9NPD5 3/20 0.93
SLCO1B1 Q9Y6L6 3/20 0.93
PPM1B O75688 1/20 0.81
MC4R P32245 1/20 0.35
MC3R P41968 1/20 0.35
KLK7 P49862 1/20 0.35
MEN1 O00255 3/20 0.34
ITGB3 P05106 1/20 0.33
ITGA2B P08514 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29711569 1.00 PTPN1 (0.95) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL29350648 1.00 PTPN1 (0.95) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL29350595 1.00 PTPN1 (0.95) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL31005304 1.00 PTPN1 (0.95) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL30788332 0.98 SLCO1B3 (0.96) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL38650007 0.98 SLCO1B3 (0.96) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL30788333 0.98 SLCO1B3 (0.96) PTPN1TFPI2NPY4RPPP5CPPM1A
Microcystin-Lr SCHEMBL29349513 0.97 PTPN1 (1.00) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL30859111 0.97 PTPN1 (0.91) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL29897131 0.97 PTPN1 (1.00) PTPN1TFPI2NPY4RPPP5CPPM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103480-A1 NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME SANOFI SA (FR) 2026-04-16 US disclosed
US-20240425862-A1 SIRNA STRUCTURES FOR HIGH ACTIVITY AND REDUCED OFF TARGET NITTO DENKO CORP (JP) 2024-12-26 US disclosed
US-20240376137-A1 NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME SANOFI SA (FR) 2024-11-14 US disclosed
US-11926831-B2 SiRNA structures for high activity and reduced off target NITTO DENKO CORPORATION (JP) 2024-03-12 US disclosed
US-11897911-B2 Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same SANOFI (FR) 2024-02-13 US disclosed
US-20220267779-A1 SIRNA STRUCTURES FOR HIGH ACTIVITY AND REDUCED OFF TARGET NITTO DENKO CORPORATION (JP) 2022-08-25 US disclosed
US-11390871-B2 SiRNA structures for high activity and reduced off target NITTO DENKO CORPORATION (JP) 2022-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11897911-B2 Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same RNMT, RRM2B, RRM2 PTPN1 3591/4885TFPI2 3382/4885NPY4R 4753/4885
US-20260103480-A1 NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME NSUN2, NSUN3, SNRPA PTPN1 3251/4885TFPI2 4365/4885NPY4R 4270/4885
US-20240376137-A1 NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME RNMT, NSUN2, ADAR PTPN1 3501/4885TFPI2 4170/4885NPY4R 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.